Advanced T-Cell Lymphomas (TCL) research hub

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.

This study is testing a new medicine called lacutamab for people with advanced T-cell lymphoma, especially certain types of skin lymphoma. It aims to see how well the medicine works and if it's safe, either on its own or with other treatments.